This study is not yet accepting patients

Parasitic Ulcer Treatment Trial

a study on Acanthamoeba Keratitis

Summary

Eligibility
for people ages 8 years and up (full criteria)
Location
at UCLA UCSF
Dates
study started
completion around
Principal Investigator
by Jeremy Keenan, MD, MPH (ucsf)
Headshot of Jeremy Keenan
Jeremy Keenan

Description

Summary

The Parasitic Ulcer Treatment Trial (PUTT) is a multi-center, parallel-group, randomized clinical trial. The purpose of this study is to determine whether including topical corticosteroids in a regimen for acanthamoeba keratitis (AK) will improve vision. Patients presenting to all enrollment centers with evidence of acanthamoeba keratitis will be eligible for the trial if there is evidence of ocular inflammation after 4 weeks of anti-amoebic therapy. Those who agree to participate will be randomized to one of two treatment groups:

  • Group 1: Topical corticosteroid
  • Group 2: Topical placebo

Keywords

Acanthamoeba Keratitis, corneal ulcer, steroids, Keratitis, Biguanides, Polihexanide, Polyhexamethylene biguanide (PHMB), Topical corticosteroid, Topical steroids

Eligibility

You can join if…

Open to people ages 8 years and up

  • AK on at least one of the following: culture, smear, PCR, shotgun sequencing, biopsy, or confocal microscopy
  • Ocular inflammation after 1 month of anti-amoebic treatment, defined as conjunctival, corneal, episcleral, or anterior chamber inflammation

You CAN'T join if...

  • Evidence or history of interstitial keratitis
  • Known herpetic keratitis, as determined from history, exam, or microbiological testing
  • Known fungal keratitis, as demonstrated from corneal scrapings
  • Corneal perforation or impending corneal perforation
  • Prior therapeutic keratoplasty for acanthamoeba keratitis
  • Unwillingness or inability to follow-up
  • No light perception in the affected eye
  • Known hypertensive response to steroids
  • Corticosteroid allergy
  • Concurrent treatment with systemic corticosteroids
  • Concurrent granulomatous amoebic encephalitis

Locations

  • University of California, Los Angeles
    Los Angeles California 90095 United States
  • University of California, San Francisco
    San Francisco California 94158 United States

Lead Scientist at University of California Health

  • Jeremy Keenan, MD, MPH (ucsf)
    Professor, Proctor Foundation, Chancellor/EVC/FAS. Authored (or co-authored) 313 research publications

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Jeremy Keenan, MD, MPH
ID
NCT06213649
Phase
Phase 3 Acanthamoeba Keratitis Research Study
Study Type
Interventional
Participants
Expecting 232 study participants
Last Updated